DaAn Gene: Progress Announcement on the Planned Change of Indirect Controlling Shareholders
Securities code: 002030 Securities abbreviation: Daan Gene Announcement number: 2026-028
Guangzhou Da'an Gene Co., Ltd.
Announcement on the progress of the planned change of indirect controlling shareholders
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and that there are no false records, misleading statements or major omissions.
1. Overview of matters
November 15, 2025 On that day, Guangzhou Financial Holding Group Co., Ltd. (hereinafter referred to as "Guangzhou Financial Holding Group"), the controlling shareholder of Guangzhou Da'an Gene Co., Ltd. (hereinafter referred to as the "Company" or "Da'an Gene"), the shareholder Guangzhou Guangyong Technology Development Co., Ltd. (hereinafter referred to as "Guangyong Technology"), the company's second largest shareholder Guangzhou Biomedicine and Health Industry Investment Co., Ltd. (hereinafter referred to as "Guangzhou Health Industry Investment", a wholly-owned subsidiary of Guangzhou Financial Holding Group) and Guangzhou Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Guangzhou Financial Holding Group") (hereinafter referred to as "GPharma Group") signed the "Framework Agreement on the Acquisition of Controlling Interests of Guangzhou Da'an Gene Co., Ltd." (hereinafter referred to as the "Framework Agreement"). GPHL or the designated related parties of Guangzhou Pharmaceutical Group intend to transfer 100% of the equity of Guangyong Technology held by Guangzhou Financial Holding Group and indirectly control the Da'an Gene shares held by Guangyong Technology; and separately transfer the Da'an Gene shares held by Guangzhou Financial Holding Group and the Da'an Gene shares held by Guangzhou Health Industry Investment through agreement transfer. portion. For specific content, please refer to the "Informative Announcement Regarding the Proposed Change of Indirect Controlling Shareholders" (announcement number: 2025-063) disclosed by the company on the Cninfo Network (http://www.cninfo.com.cn) on November 18, 2025.
On May 15, 2026, the company received the "Notification Letter Regarding the Signing of the Agreement for the Acquisition of Controlling Interest of Guangzhou Da'an Gene Co., Ltd." from Guangzhou Financial Holding Group, Guangyong Technology, and Guangzhou Health Investment respectively. The prerequisites agreed under the "Framework Agreement" have been reached, and GPHL has determined that the final transferee is its wholly-owned subsidiary Guangzhou GP Capital Co., Ltd. (hereinafter referred to as "GPPC"). The parties to the agreement have signed on May 14, 2026 On the same day, formal transaction documents such as the "Agreement on the Acquisition of Controlling Equity of Guangzhou Da'an Gene Co., Ltd." (hereinafter referred to as the "Equity Acquisition Agreement") with effective conditions were signed. The attached effective conditions are that the parties to the transaction obtain formal approval of the transaction from the superior state-owned assets/financial management department and other competent government departments. The asset appraisal report involved in this equity transfer still needs to complete the filing process. For details, please refer to the "Progress Announcement on the Proposed Change of Indirect Controlling Shareholders" disclosed by the company on the cninfo.com (http://www.cninfo.com.cn) on May 16, 2026 (announcement number: 2026-018).
2. Progress
On July 21, 2026, the company received the "Notification Letter from Guangzhou Financial Holding Group on Matters Related to the Equity Transfer Approved by the State-owned Assets Supervision and Administration Department" (Guangzhou Financial Holding Letter [2026] No. 46). The two parties to the transaction have respectively obtained the approval of the transaction from the Guangzhou Municipal Finance Bureau and the State-owned Assets Supervision and Administration Commission of the Guangzhou Municipal People's Government. At the same time, the relevant asset evaluation reports involved in this equity change have completed the filing process. The "Equity Acquisition Agreement" officially came into effect.
3. Other instructions and risk warnings
This change in equity still requires compliance confirmation from the Shenzhen Stock Exchange and application to the Shenzhen Branch of China Securities Depository and Clearing Co., Ltd. for share transfer registration procedures. There is still some uncertainty as to whether and when the relevant approval procedures will be passed. The company will pay close attention to the progress and fulfill its information disclosure obligations in a timely manner. Investors are advised to pay attention to investment risks.
Announcement is hereby made.
Board of Directors of Guangzhou Da'an Gene Co., Ltd.
July 21, 2026